Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 6226 AL 6240

Nanotherapeutics for Alzheimer's disease (AD): Past, present and future

Fazil M, Shadab, Baboota S, Sahni JK, Ali J.

J Drug Target. 2012 Feb;20(2):97-113. doi: 10.3109/1061186X.2011.607499. Epub 2011 Oct 25.

Rosiglitazone and pioglitazone for the treatment of Alzheimer's disease

Miller BW, Willett KC, Desilets AR.

Ann Pharmacother. 2011 Nov;45(11):1416-24. doi: 10.1345/aph.1Q238. Epub 2011 Oct 25.

Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer's disease: implications to mitochondria-targeted antioxidant therapeutics

Reddy PH, Tripathi R, Troung Q, Tirumala K, Reddy TP, Anekonda V, Shirendeb UP, Calkins MJ, Reddy AP, Mao P, Manczak M.

Biochim Biophys Acta. 2012 May;1822(5):639-49. doi: 10.1016/j.bbadis.2011.10.011. Epub 2011 Oct 19.

Hybrid-based multi-target ligands for the treatment of Alzheimer's disease

Rampa A, Belluti F, Gobbi S, Bisi A.

Curr Top Med Chem. 2011 Nov;11(22):2716-30. doi: 10.2174/156802611798184409.

Multitarget-directed ligands: innovative chemical probes and therapeutic tools against Alzheimer's disease

Bolognesi ML, Simoni E, Rosini M, Minarini A, Tumiatti V, Melchiorre C.

Curr Top Med Chem. 2011 Nov;11(22):2797-806. doi: 10.2174/156802611798184373.

1,8-Naphthyridine derivatives as cholinesterases inhibitors and cell Ca2+ regulators, a multitarget strategy for Alzheimer's disease

Egea J, de los Rios C.

Curr Top Med Chem. 2011 Nov;11(22):2807-23. doi: 10.2174/156802611798184418.

α7 Nicotinic receptor modulators for cognitive deficits in schizophrenia and Alzheimer's disease

Geerts H.

Expert Opin Investig Drugs. 2012 Jan;21(1):59-65. doi: 10.1517/13543784.2012.633510. Epub 2011 Nov 3.

Multi-target-directed ligands in Alzheimer's disease treatment

Bajda M, Guzior N, Ignasik M, Malawska B.

Curr Med Chem. 2011;18(32):4949-75. doi: 10.2174/092986711797535245.

Challenges associated with curcumin therapy in Alzheimer disease

Belkacemi A, Doggui S, Dao L, Ramassamy C.

Expert Rev Mol Med. 2011 Nov 4;13:e34. doi: 10.1017/S1462399411002055.

Spotlight on rivastigmine transdermal patch: in dementia of the Alzheimer's type

Dhillon S.

Drugs Aging. 2011 Nov 1;28(11):927-30. doi: 10.2165/11207090-000000000-00000.

Long-term progression of Alzheimer's disease in patients under antidementia drugs

Gillette-Guyonnet S, Andrieu S, Nourhashemi F, Gardette V, Coley N, Cantet C, Gauthier S, Ousset PJ, Vellas B; REAL.FR study group.

Alzheimers Dement. 2011 Nov;7(6):579-92. doi: 10.1016/j.jalz.2011.02.009.

Amelioration of amyloid β-induced cognitive deficits by Zataria multiflora Boiss. essential oil in a rat model of Alzheimer's disease

Majlessi N, Choopani S, Kamalinejad M, Azizi Z.

CNS Neurosci Ther. 2012 Apr;18(4):295-301. doi: 10.1111/j.1755-5949.2011.00237.x. Epub 2011 Feb 16.

Relevance of the chronobiological and non-chronobiological actions of melatonin for enhancing therapeutic efficacy in neurodegenerative disorders

Cecon E, Markus RP.

Recent Pat Endocr Metab Immune Drug Discov. 2011 May;5(2):91-9. doi: 10.2174/187221411799015381.

Efficacy and tolerability of a once daily formulation of Ginkgo biloba extract EGb 761® in Alzheimer's disease and vascular dementia: results from a randomised controlled trial

Ihl R, Tribanek M, Bachinskaya N; GOTADAY Study Group.

Pharmacopsychiatry. 2012 Mar;45(2):41-6. doi: 10.1055/s-0031-1291217. Epub 2011 Nov 15.

Interacting with γ-secretase for treating Alzheimer's disease: from inhibition to modulation

Panza F, Frisardi V, Solfrizzi V, Imbimbo BP, Logroscino G, Santamato A, Greco A, Seripa D, Pilotto A.

Curr Med Chem. 2011;18(35):5430-47. doi: 10.2174/092986711798194351.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias